Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2025-12-24 @ 9:09 PM
NCT ID:
NCT00717704
Eligibility Criteria:
Inclusion Criteria:
* Have a solid tumor malignancy that is metastatic or locally advanced/unresectable
* Progression through standard therapy
* Histological documentation of cancer
* Must be off prior chemotherapy or radiation therapy for at least 3 weeks
* Must have adequate organ and marrow function prior to the start of study treatment as defined by the protocol
* Must be able to swallow oral medication (dasatinib must be swallowed whole)
* Must be available for protocol-required follow-up
Exclusion Criteria:
* Patients with a malignancy (other than the one treated in this study) which required radiotherapy or systemic therapy within the past 5 years
* Symptomatic brain metastasis that is either untreated or uncontrolled by surgery and or radiotherapy
* A known, prior, severe (NCI CTC Grade 3/Grade 4) history of hypersensitivity reaction to a drug formulated in Cremophor (polyoxyethylated castor oil)
* A serious, uncontrolled medical disorder or active infection including pericardial or pleural effusion of any grade,uncontrolled or significant cardiovascular disease,a bleeding disorder.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00717704
Study Brief:
Protocol Section:
NCT00717704